Browse drugs

…d due to lack of efficacy. Tolerability was generally good. For atogepant, six patients stopped due to adverse events, most commonly fati…

…); −2.5 (IQR:(−5.75)-0) for rimegepant and −2 (IQR:(−12)-0) for atogepant. A ≥50% MMDw9–12 reduction was achieved by 25% overall, 25% wit…

…clusion and Relevance Results suggest that the effectiveness of atogepant in chronic migraine, in terms of reducing monthly migraine days…

…ays). During the study period, 30 patients (55.6%) discontinued atogepant. The mean duration until discontinuation was 2.7±1.7 months. Th…

…ed in 81% (N=13) of treatments: 2 atogepant, 1 erenumab, and 10 fremanezumab. A mean of 11 MMDs and 52 HIT6 score were recorded at beginning…

…Most patients were women with CM and prior mAb–antiCGRP failure.Atogepant led to a significant but modest MDM/TDM reduction, consistent w…

… measured by the reduction in monthly migraine days. To analyse atogepant’s safety, adverse events related to this drug were recorded.Pat…

…lonal antibody, 23 (41,8%) with galcanezumab and 7 (12,7%) with erenumab.At the end of the follow-up 39 (70,9%) patients had discontinue…

…ore W12. Three patients combined atogepant with botulinum toxin.Atogepant was effective in 30% (n=9), 20% (n=6) showed partial improvemen…

…worldwide and requires effective and safe long-term treatments. Atogepant, an oral CGRP receptor antagonist, has shown clinical efficacy,…

…of amitriptyline, flunarizine, topiramate, and botulinum toxin, atogepant 60 mg daily was initiated in August 2024. Three months later, m…

…RP antibodies. Treatment: 56 (82.6%) atogepant and nine (13.8%) rimegepant.Response rate: 18 (28.1%) had CR, six (9.4%) presented PR, 28 (…